Lupin's Indore Plant Gets 6 Observations After USFDA Inspection
Written By : sheeba farhat
Published On 2026-02-11 14:56 GMT | Update On 2026-02-11 14:56 GMT
Advertisement
Mumbai: Pharma major Lupin has announced the completion of a United States Food and Drug Administration (USFDA) inspection at its Pithampur Unit-2 manufacturing facility in Indore.
The inspection was conducted between January 14 and January 25, 2019. The company stated that the inspection concluded with six observations.
Lupin said it is confident of addressing the observations satisfactorily within the stipulated timeline.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.